MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector

Yuan Hao Chen, Brandon K. Harvey, Alexander F. Hoffman, Yun Wang, Yung Hsiao Chiang, Carl R. Lupica

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

This study determined the consequences of dopamine denervation of the striatum on synaptic plasticity and prevention of these changes with gene therapy using an adeno-associated viral vector (AAV) expressing glial cell line-derived neurotrophic factor (GDNF). C57BL6/J mice were injected with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); long-term depression (LTD) or potentiation (LTP) were measured in vitro. Fast-scan cyclic voltammetry measured electrically released dopamine from a functionally relevant pool in these same striatal slices. After MPTP, dopamine release and uptake were greatly diminished, and LTP and LTD were blocked in the striatal slices. The loss of plasticity resulted directly from the loss of dopamine since its application rescued synaptic plasticity. Striatal GDNF expression via AAV, before MPTP, significantly protected against the loss of dopamine and prevented the blockade of corticostriatal LTP. These data demonstrate that dopamine plays a role in supporting several forms of striatal plasticity and that GDNF expression via AAV prevents the loss of dopamine and striatal plasticity caused by MPTP. We propose that impairment of striatal plasticity after dopamine denervation plays a role in the symptomology of Parkinson's disease and that AAV expression of neurotrophic factors represents a tenable approach to protecting against or slowing these neurobiological deficits.

Original languageEnglish
Pages (from-to)261-275
Number of pages15
JournalFASEB Journal
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Corpus Striatum
Neuronal Plasticity
neurotrophins
neuroglia
dopamine
Plasticity
Dopamine
cell lines
Long-Term Potentiation
Denervation
Gene therapy
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
gene therapy
neurotoxins
4-phenyl-1,2,3,6-tetrahydropyridine
neuroplasticity
Parkinson disease
Nerve Growth Factors
Neurotoxins

Keywords

  • Cyclic voltammetry
  • Gene therapy
  • LTD
  • LTP
  • Parkinson's disease

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology
  • Medicine(all)

Cite this

MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. / Chen, Yuan Hao; Harvey, Brandon K.; Hoffman, Alexander F.; Wang, Yun; Chiang, Yung Hsiao; Lupica, Carl R.

In: FASEB Journal, Vol. 22, No. 1, 01.2008, p. 261-275.

Research output: Contribution to journalArticle

Chen, Yuan Hao ; Harvey, Brandon K. ; Hoffman, Alexander F. ; Wang, Yun ; Chiang, Yung Hsiao ; Lupica, Carl R. / MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. In: FASEB Journal. 2008 ; Vol. 22, No. 1. pp. 261-275.
@article{02c9fa6017584147ba7505492bdac160,
title = "MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector",
abstract = "This study determined the consequences of dopamine denervation of the striatum on synaptic plasticity and prevention of these changes with gene therapy using an adeno-associated viral vector (AAV) expressing glial cell line-derived neurotrophic factor (GDNF). C57BL6/J mice were injected with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); long-term depression (LTD) or potentiation (LTP) were measured in vitro. Fast-scan cyclic voltammetry measured electrically released dopamine from a functionally relevant pool in these same striatal slices. After MPTP, dopamine release and uptake were greatly diminished, and LTP and LTD were blocked in the striatal slices. The loss of plasticity resulted directly from the loss of dopamine since its application rescued synaptic plasticity. Striatal GDNF expression via AAV, before MPTP, significantly protected against the loss of dopamine and prevented the blockade of corticostriatal LTP. These data demonstrate that dopamine plays a role in supporting several forms of striatal plasticity and that GDNF expression via AAV prevents the loss of dopamine and striatal plasticity caused by MPTP. We propose that impairment of striatal plasticity after dopamine denervation plays a role in the symptomology of Parkinson's disease and that AAV expression of neurotrophic factors represents a tenable approach to protecting against or slowing these neurobiological deficits.",
keywords = "Cyclic voltammetry, Gene therapy, LTD, LTP, Parkinson's disease",
author = "Chen, {Yuan Hao} and Harvey, {Brandon K.} and Hoffman, {Alexander F.} and Yun Wang and Chiang, {Yung Hsiao} and Lupica, {Carl R.}",
year = "2008",
month = "1",
doi = "10.1096/fj.07-8797com",
language = "English",
volume = "22",
pages = "261--275",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "1",

}

TY - JOUR

T1 - MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector

AU - Chen, Yuan Hao

AU - Harvey, Brandon K.

AU - Hoffman, Alexander F.

AU - Wang, Yun

AU - Chiang, Yung Hsiao

AU - Lupica, Carl R.

PY - 2008/1

Y1 - 2008/1

N2 - This study determined the consequences of dopamine denervation of the striatum on synaptic plasticity and prevention of these changes with gene therapy using an adeno-associated viral vector (AAV) expressing glial cell line-derived neurotrophic factor (GDNF). C57BL6/J mice were injected with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); long-term depression (LTD) or potentiation (LTP) were measured in vitro. Fast-scan cyclic voltammetry measured electrically released dopamine from a functionally relevant pool in these same striatal slices. After MPTP, dopamine release and uptake were greatly diminished, and LTP and LTD were blocked in the striatal slices. The loss of plasticity resulted directly from the loss of dopamine since its application rescued synaptic plasticity. Striatal GDNF expression via AAV, before MPTP, significantly protected against the loss of dopamine and prevented the blockade of corticostriatal LTP. These data demonstrate that dopamine plays a role in supporting several forms of striatal plasticity and that GDNF expression via AAV prevents the loss of dopamine and striatal plasticity caused by MPTP. We propose that impairment of striatal plasticity after dopamine denervation plays a role in the symptomology of Parkinson's disease and that AAV expression of neurotrophic factors represents a tenable approach to protecting against or slowing these neurobiological deficits.

AB - This study determined the consequences of dopamine denervation of the striatum on synaptic plasticity and prevention of these changes with gene therapy using an adeno-associated viral vector (AAV) expressing glial cell line-derived neurotrophic factor (GDNF). C57BL6/J mice were injected with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); long-term depression (LTD) or potentiation (LTP) were measured in vitro. Fast-scan cyclic voltammetry measured electrically released dopamine from a functionally relevant pool in these same striatal slices. After MPTP, dopamine release and uptake were greatly diminished, and LTP and LTD were blocked in the striatal slices. The loss of plasticity resulted directly from the loss of dopamine since its application rescued synaptic plasticity. Striatal GDNF expression via AAV, before MPTP, significantly protected against the loss of dopamine and prevented the blockade of corticostriatal LTP. These data demonstrate that dopamine plays a role in supporting several forms of striatal plasticity and that GDNF expression via AAV prevents the loss of dopamine and striatal plasticity caused by MPTP. We propose that impairment of striatal plasticity after dopamine denervation plays a role in the symptomology of Parkinson's disease and that AAV expression of neurotrophic factors represents a tenable approach to protecting against or slowing these neurobiological deficits.

KW - Cyclic voltammetry

KW - Gene therapy

KW - LTD

KW - LTP

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=38049185043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049185043&partnerID=8YFLogxK

U2 - 10.1096/fj.07-8797com

DO - 10.1096/fj.07-8797com

M3 - Article

C2 - 17690153

AN - SCOPUS:38049185043

VL - 22

SP - 261

EP - 275

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 1

ER -